Gilead’s Descovy (Emtricitabine, Tenofovir Alafenamide) Receives NMPA ‘s (CFDA) Approval for HIV-1 Infection

 Gilead’s Descovy (Emtricitabine, Tenofovir Alafenamide) Receives NMPA ‘s (CFDA) Approval for HIV-1 Infection

Gilead’s Descovy (Emtricitabine, Tenofovir Alafenamide) Receives NMPA ‘s (CFDA) Approval for HIV-1 Infection

Shots:

  • The approval is based on three P-III study (104,111 & 109) results assessing Genvoya (elvitegravir/ cobicistat /emtricitabine /tenofovir alafenamide /150 / 150/ 200/ 10mg, E/C/F/TAF) vs Stribild (E/C/F/TDF,150 mg/ 150 mg/ 200 mg/tenofovir disoproxil fumarate 300 mg) in adults for 144 wks.
  • The pooled study demonstrated non-inferiority data, meeting 1EPs compared with Stribild and improvement in certain bone and renal parameters
  • Descovy (emtricitabine 200 mg/tenofovir alafenamide 10 mg and emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF) is a TAF based treatment, approved by EU and the US for HIV-1 infection in adults

Click here to read full press release/ article | Ref: Gilead | Image: CNBC

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post